Blog
Join WuXi AppTec at the 42nd American College of Toxicology Annual Meeting
WuXi AppTec is excited to exhibit at this year’s 42nd Annual Meeting of the American College of Toxicology (ACT). The event runs from November 14-17, 2021, and will be held at Gaylord National Harbor located just outside Washington D.C. The ACT Annual Meeting brings...
In The News: WuXi AppTec Experts In The Drug Development Community (Jan-July 2021)
WuXi AppTec Laboratory Testing Division experts continually weigh in on emerging trends and stay updated on salient drug development topics. These experts routinely contribute to industry publications. Here’s where they’ve been featured in the first half of 2021....
Testing Toxicity to Advance to Phase I Clinical Trials
Preclinical research teams enter each drug testing project with the same hope – that the drug will meet all the safety requirements in order to advance to phase I clinical trials in humans. In laboratory experiments, scientists will test their ideas for new...
Managing Critical Reagents: An Essential Part of Your Bioanalytical Strategy
Critical reagents are an essential part of bioanalytical testing for large molecule preclinical and clinical studies. These essential components help determine the accuracy of the analyte, precision and performance of ligand binding assays (LBAs), which are key to...
Good Communication Essential To Successful Preclinical Testing
For both large and small drug development companies, good communication displayed throughout the preclinical testing process is essential to success. Project leaders who exhibit great awareness, flexibility and communication skills can’t be undervalued in the timely...
Understanding Differences in Regulatory Requirements Vital to Efficient Design of Preclinical Programs
There are many factors involved in designing a preclinical drug safety assessment program, but among the priorities is having a good understanding of the different requirements from the various regulatory agencies in which the Investigative New Drug (IND) will be...
PROTACs and Their Role in Catalyzing Health Solutions
PROTACs, otherwise known as PROteolysis TArgeting Chimera, emerged as a novel therapeutic modality in drug development and currently show promising clinical results for tackling some of the most complex diseases. PROTACs are designed to leverage the body’s internal...
An Important First Step in the Design of a Preclinical Program
In the design of a preclinical program, identifying and understanding the broad classification of the molecule is the priority. Is it a small molecule, a chemical, a manufactured drug? Or is it a biologic or a large molecule, a construct of amino acids, providing a...
Information Exchange is Essential Prior to Designing Preclinical Drug Development Programs
Having the full spectrum of information about the early investigative work completed, as well as safety assessment goals and expectations for the successful development of a new drug, is essential in order to create the most effective preclinical strategies. Dr. Mark...
PART 1 – Understanding New Modalities: Oligonucleotides and Bispecific Antibodies
As our understanding of genomics and biological pathways expands, human diseases, once thought untreatable through conventional therapies, are well within our realm of intervention. Oligonucleotides ("oligos") and bispecific antibodies (BsAbs) are two new modalities...
PART 2 – Understanding New Modalities: Prodrugs, Cell/Gene Therapy and Fusion Proteins
New drug modalities, including oligonucleotides, bispecific antibodies, prodrugs, cell and gene therapies, and fusion proteins, offer new ways to treat human diseases once considered "untreatable." Cell and gene therapies have been around for years, but advancing...
Grand Opening of New R&D Center in China
The Nanjing Branch of the DMPK Business Unit Begins Operation Grand Opening On May 24, 2021, the Nanjing Branch of the DMPK business unit of WuXi AppTec’s Laboratory Testing Division opened for business in a grand fashion. The event attracted many presenters,...